The IMID Forum
Discussing RA: May 2024
Jun 6, 2024
Join Professor Janet Pope and Dr Sofia Ramiro on The IMID Forum as they discuss the long-term safety of JAK inhibitors in RA. They delve into papers comparing tofacitinib versus TNFi in cardiovascular risk and the efficacy of upadacitinib over five years. The podcast also explores the importance of proper treatment to reduce risks and the balancing act of benefits versus risks in JAK inhibitor prescriptions for inflammatory diseases.
30:08
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Comparative safety analysis between Tofacitinib and TNF inhibitors in RA patients with cardiovascular risk factors.
- Long-term efficacy and safety data for Upadacitinib in rheumatoid arthritis patients over five years.
Deep dives
Study on Safety Profile of Jack Inhibitors and TNF Inhibitors in Rheumatoid Arthritis Patients
A new analysis compared the safety profiles of Jack inhibitor, Tofacitinib, and TNF inhibitors in rheumatoid arthritis patients focusing on cardiovascular events. The study involved older patients with cardiovascular risk factors and high disease activity who were also on background methotrexate. Although numerically more cardiovascular events were seen in the Tofacitinib group, the study was inconclusive due to a wider confidence interval. Patients with a history of atherosclerotic cardiovascular disease were at higher risk, emphasizing the importance of patient history in assessing risk.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
